Last reviewed · How we verify
Oseltamivir Phosphate For Oral Suspension
Oseltamivir Phosphate For Oral Suspension is a Neuraminidase inhibitor Small molecule drug developed by The Affiliated Hospital of Qingdao University. It is currently FDA-approved for Treatment of acute uncomplicated influenza A and B infection in patients 2 weeks of age and older, Prophylaxis of influenza A and B in patients 1 year of age and older.
Oseltamivir phosphate is a neuraminidase inhibitor that blocks the release of influenza virus particles from infected cells, preventing viral spread.
Oseltamivir phosphate is a neuraminidase inhibitor that blocks the release of influenza virus particles from infected cells, reducing viral spread. Used for Treatment of acute uncomplicated influenza A and B infection in patients ≥2 weeks of age, Prophylaxis of influenza A and B in patients ≥1 year of age.
At a glance
| Generic name | Oseltamivir Phosphate For Oral Suspension |
|---|---|
| Sponsor | The Affiliated Hospital of Qingdao University |
| Drug class | Neuraminidase inhibitor |
| Target | Influenza neuraminidase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Oseltamivir is a prodrug that is converted to its active form (oseltamivir carboxylate) in the body. The active metabolite inhibits influenza neuraminidase, an enzyme on the viral surface that cleaves sialic acid receptors, thereby trapping newly formed virus particles on the cell surface and preventing their release and dissemination to other cells.
Approved indications
- Treatment of acute uncomplicated influenza A and B infection in patients 2 weeks of age and older
- Prophylaxis of influenza A and B in patients 1 year of age and older
Common side effects
- Nausea
- Vomiting
- Abdominal pain
- Headache
- Diarrhea
Key clinical trials
- Study to Assess the Safety and Efficacy of ZX-7101A for Oral Suspension in Chinese Pediatric Participants 2 to 11 Years of Age With Influenza (PHASE3)
- Study to Assess the Safety and Efficacy of ZX-7101A in Children Aged 5-11 Years With Influenza (PHASE3)
- Study on the Human Bioequivalence of Oseltamivir Phosphate For Oral Suspension (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oseltamivir Phosphate For Oral Suspension CI brief — competitive landscape report
- Oseltamivir Phosphate For Oral Suspension updates RSS · CI watch RSS
- The Affiliated Hospital of Qingdao University portfolio CI
Frequently asked questions about Oseltamivir Phosphate For Oral Suspension
What is Oseltamivir Phosphate For Oral Suspension?
How does Oseltamivir Phosphate For Oral Suspension work?
What is Oseltamivir Phosphate For Oral Suspension used for?
Who makes Oseltamivir Phosphate For Oral Suspension?
What drug class is Oseltamivir Phosphate For Oral Suspension in?
What development phase is Oseltamivir Phosphate For Oral Suspension in?
What are the side effects of Oseltamivir Phosphate For Oral Suspension?
What does Oseltamivir Phosphate For Oral Suspension target?
Related
- Drug class: All Neuraminidase inhibitor drugs
- Target: All drugs targeting Influenza neuraminidase
- Manufacturer: The Affiliated Hospital of Qingdao University — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Treatment of acute uncomplicated influenza A and B infection in patients 2 weeks of age and older
- Indication: Drugs for Prophylaxis of influenza A and B in patients 1 year of age and older
- Compare: Oseltamivir Phosphate For Oral Suspension vs similar drugs
- Pricing: Oseltamivir Phosphate For Oral Suspension cost, discount & access